Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin prophylaxis for COVID-19 in cancer patients
NCT04369365Phase 2Completed
- Start
- Apr 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of azithromycin in coronavirus disease 2019 (COVID-19). Primary endpoint: Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections at 12 weeks. Started Apr 2020; status: completed.
02
Drugs
azithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04369365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369365.